Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2018

View Archived Issues

Optimized 1,4-oxazine BACE1 inhibitor shows improved safety profile in preclinical studies

When a bear spits in the woods

Microbiome metabolites and host responses

Neutrophil-lookalike membranes fight arthritis

Host changes after Zika virus infection

Carbon dioxide aggravates COPD

Different vaccination routes lead to different protection

Sichuan Kelun-Biotech Biopharmaceutical divulges MAP3K5 inhibitors

Korean researchers synthesize new LRRK2 inhibitors

Daiichi Sankyo discovers bacterial tryptophanase inhibitors

Domainex patents new IKK-E, TBK1 and SIK2 kinase inhibitors

New model of thrombopoietin receptor activation in myeloproliferative neoplams

Small-molecule CNS-penetrant autophagy enhancers suitable for study in vivo identified

Within patients, untreated metastases largely share drivers

BDD and Cingulate complete license agreement with OralogiK-enabled triple pulse products

Oryzon receives approval to initiate phase IIa REIMAGINE study of vafidemstat in aggressiveness

ZNF281 inhibits neuronal differentiation and predicts the prognosis of neuroblastoma

CureDuchenne invests in 4D Molecular Therapeutics

FDA issues complete response letter for mepolizumab in COPD

Grifols signs agreement to support research in rare and chronic diseases

Roche opens enrollment in phase III study of RO-6867461 for DME

Sareum selects SDC-1801 from TYK2 inhibitor program for advancement in autoimmune diseases

AstraZeneca initiates first-in-human study of AZD-8233

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...